Prof. Andy Goren, MD, MD (hc)
President, Chief Medical Officer
Prof. Andy Goren has over 20 years of experience in research, development and commercialization of breakthrough therapeutics and diagnostics. Among the list of many firsts in dermatology, Prof. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid test for predicting minoxidil response in androgenetic alopecia.
Prof. Goren is actively involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy induced alopecia, excessive hair shedding, female sexual dysfunction and COVID-19. His latest research involves the use of anti-androgen therapy for the treatment of COVID-19.
Prof. Goren currently serves as an External Medical Advisor and a Co-Researcher, Trichology Unit, Ramon y Cajal Hospital, Madrid, Spain, a Visiting Professor of Dermatology, Department of Dermatology and Venereology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, a Medical Doctor at the Skin & Cosmetic Research Dept., Shanghai Skin Disease Hospital, Shanghai, China and a Visiting Medical Doctor, Department of Dermatology and Venereology, L.T.M. Medical College Sion, Mumbai, India. Clinical Research Director at Samel Hospital, Manaus, Brazil. Prof. Goren has published dozens of peer-reviewed original medical research papers. He is an honorary as well as ordinary member of several dermatology societies world-wide as well as a regular lecturer at dermatology congresses around the world. He held numerous appearances and interviews on mainstream TV, radio, and prestigious newspapers.